- Home
- LGN vs NAMS Comparison
LGN vs NAMS Comparison
Compare LGN & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LGN | NAMS |
|---|---|---|
| Founded | 1963 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LGN | NAMS |
|---|---|---|
| Price | $50.91 | $30.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 9 |
| Target Price | $44.90 | ★ $47.33 |
| AVG Volume (30 Days) | ★ 856.7K | 810.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.13 | $25.64 |
| Revenue Next Year | $42.76 | $530.85 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.31 | $14.06 |
| 52 Week High | $58.00 | $42.00 |
Technical Indicators
Market Signals| Indicator | LGN | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 47.52 | 34.90 |
| Support Level | $42.97 | $23.48 |
| Resistance Level | $52.50 | $37.43 |
| Average True Range (ATR) | 3.45 | 1.84 |
| MACD | -0.24 | -0.62 |
| Stochastic Oscillator | 41.98 | 9.93 |
Price Performance
Historical ComparisonAbout LGN Legence Corp.
Legence Corp is a provider of engineering, installation and maintenance services for mission-critical systems in buildings. It focuses on high-growth sectors that have technically demanding buildings, including technology, life sciences, healthcare and education. The company specializes in designing, fabricating and installing complex HVAC, process piping and other mechanical, electrical and plumbing (MEP) systems for new facilities and upgrading HVAC, lighting and building controls in existing facilities to make them more energy efficient and sustainable.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.